A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

被引：0
|
作者：
Montesinos, Pau
Al-Ali, Haifa
Alonso-Dominguez, Juan M.
Jentzsch, Madlen
Jongen-Lavrencic, Mojca
Martelli, Maria Paola
Rollig, Christoph
Sica, Simona
Iadevaia, Riham
Yablonski, Kaitlin
Wang, Tianli
Mahmood, Zafar
Koenen, Giedre
Schmidt, Hank
Yang, Jingsong
Yee, Karen
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT124
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Gojo, Ivana
    Perl, Alexander
    Luger, Selina
    Baer, Maria R.
    Norsworthy, Kelly J.
    Bauer, Kenneth S.
    Tidwell, Michael
    Fleckinger, Stephanie
    Carroll, Martin
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1217 - 1227
  • [32] Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Tang, Man Wai
    van der Tuin, Deborah
    Aydin, Mesire
    Heijmans, Jarom
    van de Loosdrecht, Arjan A.
    Meijer, Ellen
    Rutten, Caroline E.
    Wondergem, Marielle
    Janssen, Jeroen J. W. M.
    Donker, Marjolein L.
    Hazenberg, Mette D.
    Zweegman, Sonja
    Biemond, Bart J.
    De Leeuw, David C.
    Nur, Erfan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 620 - 625
  • [33] Odyssey: A First-in-Human Study of the Aldehyde Dehydrogenase (ALDH) Inhibitor Abd-3001 in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Benajiba, Lina
    Colle, Julien
    Heiblig, Mael
    Loron, Sandrine
    Soret-Dulphy, Juliette
    Berchard, Paul
    Yazir, Muhube
    Basset, Laurent
    Venton, Geoffroy
    Larcher, Marie-Virginie
    De Oliveira, Rafael Daltro
    Fossard, Gaelle
    Martin, Guillaume
    Perez, Mileidys
    Ceylan, Ismael
    Pelletier, Annick
    Kiladjian, Jean-Jacques
    Costello, Regis
    BLOOD, 2024, 144 : 6001 - 6002
  • [34] Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Cortes, Jorge
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04): : 244 - 251
  • [35] Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
    Roboz, Gail J.
    Yee, Karen
    Verma, Amit
    Borthakur, Gautam
    de la Fuente Burguera, Adolfo
    Sanz, Guillermo
    Mohammad, Helai P.
    Kruger, Ryan G.
    Karpinich, Natalie O.
    Ferron-Brady, Geraldine
    Acusta, Andre
    Del Buono, Heather
    Collingwood, Therese
    Ballas, Marc
    Dhar, Arindam
    Wei, Andrew H.
    LEUKEMIA & LYMPHOMA, 2022, 63 (02) : 463 - 467
  • [36] Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Pemmaraju, Naveen
    Borate, Uma
    Solh, Melhem
    Borthakur, Gautam M.
    DeZern, Amy E.
    Zhang, Chao
    Powell, Ben
    Severson, Paul
    Inokuchi, Kerry
    Matusow, Bernice
    Halladay, Jason
    Hsu, Ching
    Watkins, Paul
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    Mims, Alice S.
    BLOOD, 2019, 134
  • [37] A first-in-human, phase 1, dose escalation study of SGR-2921 as monotherapy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.
    Weiss, Daniel
    Dinardo, Courtney Denton
    Strickland, Stephen Anthony
    Skikne, Barry
    Zeidan, Amer Methqal
    Traer, Elie A.
    Carraway, Hetty E.
    Carraway, Hetty E.
    Frankel, Stanley R.
    Wang, Jacky
    Pirie-Shepherd, Steven Robert
    Piccotti, Joseph R.
    Wright, Duncan Hamish
    Akinsanya, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Becker, Pamela S.
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland B.
    Estey, Elihu H.
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 1023 - 1029
  • [39] Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome
    Mabrey, Frances Linzee
    Gardner, Kelda M.
    Dorcy, Kathleen Shannon
    Perdue, Andrea
    Smith, Heather A.
    Davis, Alicyn M.
    Hammer, Cody
    Rizzuto, Donelle
    Jones, Sunny
    Quach, Kim
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Walter, Roland B.
    Appelbaum, Frederick R.
    Estey, Elihu H.
    Becker, Pamela S.
    BLOOD ADVANCES, 2020, 4 (04) : 611 - 616
  • [40] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated on Versus Off Study
    Buckley, Sarah A.
    Percival, Mary-Elizabeth M.
    Othus, Megan
    Halpern, Anna B.
    Huebner, Emily M.
    Shaw, Carole
    Hendrie, Paul C.
    Shadman, Mazyar
    Becker, Pamela S.
    Walter, Roland B.
    Estey, Elihu H.
    BLOOD, 2016, 128 (22)
12345